apceth to present at European Society of Gene and Cell Therapy Annual Congress

Munich, Germany, Oct 10, 2018. apceth Biopharma is proud to announce that it will be presenting its latest results on apceth-201 in graft-vs-host-disease (GvHD) at this year’s ESGCT Annual Congress “Changing Modern Medicine: Stem Cells & Gene Therapy”. The meeting will take place in Lausanne, Switzerland, on October 16-19, 2018.
apceth‘s poster is titled: “Human Mesenchymal Stem Cells Genetically Engineered to Express Alpha-1 Anti-Trypsin (apceth-201) Confer a Long-Term Survival Benefit in Lethal Mouse Models of Graft-Versus-Host-Disease”. It has poster number P126 and will be presented during the session on Thursday, October 18.

For further information on ESGCT Annual Congress, please visit https://www.esgct.eu/Congress/Current-Congress.aspx